Clovis: Jumps on positive data for drug in ovarian cancer study

Clovis Oncology

19/03/2021 13:14

** Shares of drugmaker  CLVS.O  jump 14.85% to $6.11
premarket 
    ** Co says its drug, Rubraca, extended the time ovarian
cancer patients survived without their disease progressing
compared to chemotherapy in a late-stage trial  urn:newsml:reuters.com:*:nBw9GtNgda
    ** The drug was tested among patients who have received two
or more prior lines of chemotherapy for a type of advanced
ovarian cancer, carrying genetic mutation called BRCA
    ** According to the American Cancer Society, over 21,000
women are estimated to be diagnosed with ovarian cancer in the
United States - CLVS
    ** The U.S. FDA last May approved Rubraca for the treatment
of adult patients with metastatic castration-resistant prostate
cancer, whose tumors have BRCA mutation  urn:newsml:reuters.com:*:nL4N2D02T4
    ** Rubraca is also approved in the U.S. as a maintenance
treatment for adults with ovarian, fallopian tube, primary
peritoneal cancers, whose disease has returned and whose tumors
have responded to a platinum-based chemotherapy
    ** CLVS up ~11% this year, as of Thursday's close 

 (Reporting by Manojna Maddipatla in Bengaluru)
 ((manojna.kalyani@thomsonreuters.com; within the U.S. +1 646
223 8780, outside the U.S. +91  80 6749 1692))